{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:14:43Z","timestamp":1779898483115,"version":"3.53.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Zhongshan Social Welfare and Basic Research Project","award":["210317223949975"],"award-info":[{"award-number":["210317223949975"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,25]]},"abstract":"<jats:p>To investigate the short-term and long-term efficacy and safety of thalidomide in the treatment of intermediate and severe \u03b2-thalassemia. We analyzed patients with intermediate and severe \u03b2-thalassemia treated at our hospital from February 2019 to February 2024. Patients who received treatment for more than 3 months were included. The efficacy of thalidomide was assessed by comparing changes in hemoglobin (Hb), ferritin, bilirubin, and Hb electrophoresis before and after treatment. Adverse drug reactions during treatment were also recorded. A total of 42 \u03b2-thalassemia patients were included, with thalidomide dosages ranging from 75 to 150 mg\/d. The response rates at 1, 3, and 6 months of treatment were 73.8% (31\/42), 75.0% (24\/32), and 94.7% (18\/19), respectively. The increase in Hb levels was primarily attributed to fetal hemoglobin (HbF). After 1 month of treatment, the HbF percentage increased from a baseline of 34.04\u2005\u00b1\u200527.58% to 56.25\u2005\u00b1\u200528.40% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). At 3 and 6 months, HbF further increased to 67.21\u2005\u00b1\u200527.12% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001) and 73.93\u2005\u00b1\u200522.96% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), respectively. The average duration of thalidomide treatment was 25.3\u2005\u00b1\u20059.2 months (range: 4\u201360 months), with 6 patients treated for over 60 months and 18 patients for over 48 months. Two homozygous patients who failed thalidomide treatment achieved Hb levels above 100 g\/L and discontinued transfusion therapy after 3 months of hydroxyurea treatment. The most common adverse reaction was somnolence, which was mild and tolerable. Thalidomide demonstrates significant and sustained therapeutic effects in \u03b2-thalassemia patients. The adverse reactions are mild and tolerable, allowing patients to continue treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000040328","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T15:03:05Z","timestamp":1730214185000},"page":"e40328","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of thalidomide in patients with \u03b2-thalassemia intermedia and major"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-7806","authenticated-orcid":false,"given":"Wendong","family":"Ju","sequence":"first","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaomin","family":"Din","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Electrocardiology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suling","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology Rheumatology, Zhongshan Boai Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Education Section, Zhongshan Boai Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"243","article-title":"Clinical practice guidelines for beta-thalassemia.","volume":"37","author":"Shang","year":"2020","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41392-021-00811-0","article-title":"Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: a randomized clinical trial.","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e13035","DOI":"10.1111\/dth.13035","article-title":"Epidermolysis bullosa pruriginosa: a rare entity which responded well to thalidomide.","volume":"32","author":"Rani","year":"2019","journal-title":"Dermatol Ther"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in beta-thalassemia.","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.blre.2018.02.001","article-title":"A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies?","volume":"32","author":"Cappellini","year":"2018","journal-title":"Blood Rev"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hum.2006.151","article-title":"Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy.","volume":"18","author":"Sadelain","year":"2007","journal-title":"Hum Gene Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia.","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41598-017-00150-7","article-title":"Reciprocal regulation of \u03b3-globin expression by exo-miRNAs: relevance to \u03b3-globin silencing in \u03b2-thalassemia major.","volume":"7","author":"Sun","year":"2017","journal-title":"Sci Rep"},{"key":"R9-20250504","first-page":"43","article-title":"Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.","volume":"10","author":"Foong","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/03630269.2013.845844","article-title":"Optimizing the dose of hydroxyurea therapy for patients with P-thalassemia intermedia (HbE-P-thalassemia): a single center study from Eastern India.","volume":"38","author":"Bohara","year":"2014","journal-title":"Hemoglobin"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3109\/08880010903271671","article-title":"Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.","volume":"26","author":"Ehsani","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00277-018-3357-y","article-title":"Efficacy of decitabine as hemoglobin F inducer in HbE\/\u03b2-thalassemia.","volume":"97","author":"Kalantri","year":"2018","journal-title":"Ann Hematol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2008.03.001","article-title":"Thalidomide therapy in a patient with thalassemia major.","volume":"41","author":"Aguilar-Lopez","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2007-01-065201","article-title":"Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis.","volume":"110","author":"Aerbajinai","year":"2007","journal-title":"Blood"},{"key":"R15-20250504","first-page":"37","article-title":"Thalidomide is more efficient than sodium butyrate in enhancing GATA-1 and EKLF gene expression in erythroid progenitors derived from HSCs with \u03b2-globin gene mutation.","volume":"10","author":"Jalali Far","year":"2016","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12955","article-title":"Thalidomide induces haematologic responses in patients with beta-thalassaemia.","volume":"99","author":"Chen","year":"2017","journal-title":"Eur J Haematol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/bjh.16272","article-title":"Safety and effectiveness of thalidomide and hydroxyurea combination in beta-thalassaemia intermedia and major: a retrospective pilot study.","volume":"188","author":"Shah","year":"2020","journal-title":"Br J Haematol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/10245332.2017.1354427","article-title":"Thalidomide has a significant effect in patients with thalassemia intermedia.","volume":"23","author":"Li","year":"2018","journal-title":"Hematology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00277-018-3395-5","article-title":"Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia.","volume":"97","author":"Ren","year":"2018","journal-title":"Ann Hematol"},{"key":"R21-20250504","first-page":"2419","article-title":"Investigation of thalassemia genotypes in large-scale populations in Zhongshan.","volume":"25","author":"Chen","year":"2015","journal-title":"Chin J Health Lab Tec"},{"key":"R22-20250504","first-page":"705","article-title":"Consensus of experts on diagnosis and treatment of non-transfusion dependent thalassemia in China (2018 edition).","volume":"39","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"657056","DOI":"10.1093\/ecam\/neq022","article-title":"The ethanol extract of fructus trichosanthis promotes fetal hemoglobin production via p38 MAPK activation and ERK inactivation in K562 Cells.","volume":"2011","author":"Li","year":"2011","journal-title":"Evid Based Complement Alternat Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcmd.2016.01.003","article-title":"The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with non-transfusion-dependent thalassemia.","volume":"57","author":"Ricchi","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI32322","article-title":"Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.","volume":"118","author":"Moutouh-de Parseval","year":"2008","journal-title":"J Clin Invest"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-11-319137","article-title":"Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.","volume":"118","author":"Meiler","year":"2011","journal-title":"Blood"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2015-09-667923","article-title":"Pomalidomide reverses \u03b3-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.","volume":"127","author":"Dulmovits","year":"2016","journal-title":"Blood"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"722502","DOI":"10.3389\/fphar.2021.722502","article-title":"Efficacy of thalidomide treatment in children with transfusion dependent \u03b2-thalassemia: a retrospective clinical study.","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1002\/ajh.24030","article-title":"Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis.","volume":"90","author":"Fozza","year":"2015","journal-title":"Am J Hematol"},{"key":"R31-20250504","first-page":"11","article-title":"Thalidomide in multiple myeloma.","volume":"14","author":"Rajkumar","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-021-04501-3","article-title":"Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.","volume":"100","author":"Bhurani","year":"2021","journal-title":"Ann Hematol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1182\/bloodadvances.2022007031","article-title":"Evaluation of the combination therapy of hydroxyurea and thalidomide in \u03b2-thalassemia.","volume":"6","author":"Ansari","year":"2022","journal-title":"Blood Adv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:52:13Z","timestamp":1746319933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":31,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040328","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}